We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


deCODE Initiates Chemical Development Collaboration with SGX

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "deCODE Initiates Chemical Development Collaboration with SGX"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

deCODE chemistry has initiated a new chemical development service collaboration with SGX Pharmaceuticals. The research performed by deCODE chemistry is aimed at developing and executing a scalable production process for SGX.

Under this collaboration SGX will gain access to deCODE’s platform for chemical development including route optimization, production of toxicology lots, cGMP production of clinical batches, physical form characterization, and all associated analytical method development and validation.

“We are pleased that SGX Pharmaceuticals chose the deCODE chemistry team for their chemical development needs,” said Dr. David Zembower, Vice President of Chemistry at deCODE. “Over the years we have continued to build upon our service platform to provide our valued clients with a rapid, cost-effective transition from selection of development candidates through entry into human clinical trials.”